3 citations
,
January 1990 in “Cancer chemotherapy and pharmacology” Topical thiols may prevent hair loss caused by certain chemotherapy drugs.
Tadalafil may reduce the risk of major heart events and blood clots in men with urinary symptoms.
29 citations
,
January 1996 in “Journal of Pharmaceutical Sciences” Finasteride poorly inhibits type 1 5AR, affecting its effectiveness.
January 2025 in “International Journal of Dermatology” Tofacitinib improved hair and nail conditions in a teen with alopecia areata.
14 citations
,
April 2023 in “Acta Dermato Venereologica” Upadacitinib effectively treated severe hair loss in a child.
1 citations
,
April 2023 in “Portuguese Journal of Dermatology and Venereology” JAK inhibitors are effective treatments for alopecia areata.
20 citations
,
January 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is the most effective treatment for alopecia areata.
April 2026 in “Frontiers in Medicine” Upadacitinib effectively treats psoriasis and lichen planus together.
9 citations
,
October 2021 in “International Journal of Dermatology” Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.
January 2026 in “Frontiers in Public Health” Baricitinib and tofacitinib have different safety patterns in treating alopecia areata.
February 2026 in “International Journal of Clinical Dermatology” A multi-drug treatment can effectively clear extensive calcinosis in juvenile dermatomyositis.
8 citations
,
February 2024 in “Burns” 39 citations
,
June 2019 in “Frontiers in Endocrinology” Lenvatinib and sorafenib are generally safe but need dose adjustments due to side effects.
July 2024 in “Journal of Investigative Dermatology” Biosimilars lower costs but don't significantly improve access.
42 citations
,
December 2007 in “American Journal of Psychiatry” Finasteride may effectively reduce Tourette's syndrome symptoms and improve life quality.
1 citations
,
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
38 citations
,
July 2010 in “Clinical, cosmetic and investigational dermatology” To treat tinea capitis in children, oral antifungal medication is necessary, with newer drugs offering shorter treatment times than the traditional griseofulvin.
May 2023 in “International Journal of Trichology” Tofacitinib may be an effective and safe treatment for hair loss in teenagers with alopecia areata.
24 citations
,
February 2007 in “Hormone and metabolic research” The substance MK386 effectively blocked testosterone conversion and reduced cell growth in certain skin cells, but inhibiting 5α-reductase alone may not greatly improve acne.
2 citations
,
February 2025 in “Archives of Dermatological Research” Baricitinib is a safe and effective alternative for alopecia areata patients who do not respond to tofacitinib.
August 2019 in “Journal of the American Academy of Dermatology” Tofacitinib may help hair regrowth in alopecia areata, but more research is needed.
2 citations
,
March 2022 in “Modern Rheumatology Case Reports” A medicine called tofacitinib worked to treat a hair loss condition linked with a muscle and skin disease.
April 2024 in “Clinical and experimental dermatology” Tofacitinib is effective for severe alopecia areata, similar to oral betamethasone.
4 citations
,
December 2024 in “Clinical Cosmetic and Investigational Dermatology” This study evaluated the efficacy and tolerability of combining baricitinib, a JAK1/2 inhibitor, with narrowband UV-B (NB-UVB) therapy in treating active nonsegmental vitiligo (NSV). Involving 52 patients in the combination group and 49 in the control group receiving oral mini-pulse methylprednisolone with NB-UVB, the study found that the combination therapy was effective and well-tolerated over a 6-month period. Recurrence rates within 6 months post-treatment were similar between groups. Minor adverse effects included itchy skin in 5.8% and erythema in 1.9% of patients in the combination group. The findings suggest this combination therapy is a promising treatment option for NSV, supporting the need for larger clinical trials.
April 2023 in “Journal of Investigative Dermatology” Blocking casein kinase 1 in skin cells can help melanocyte precursors move better, potentially helping with conditions like vitiligo or gray hair.
49 citations
,
August 1996 in “The Journal of Clinical Endocrinology and Metabolism” The combination of cyproterone acetate and testosterone enanthate is highly effective in preventing sperm production and could be a good reversible male contraceptive.
114 citations
,
December 1951 in “Archives of Dermatology” Aminopterin strongly suppresses epithelial tissues and can treat certain skin conditions but has significant side effects.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Adapalene, Diosmin, and Azelastine may effectively treat onchocerciasis.
April 2016 in “Journal of The American Academy of Dermatology” Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Adapalene, Diosmin, and Azelastine may effectively treat onchocerciasis.